National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Encorafenib (Braftovi®), binimetinib (Mektovi®) for the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.


NCPE Assessment Process Complete
Rapid review commissioned 08/01/2019
Rapid review completed 23/01/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of encorafenib and binimetinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations; May 2019